| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9321433 | European Urology Supplements | 2005 | 10 Pages |
Abstract
In summary, LHRH agonist therapy is important in the treatment of both early and advanced prostate cancer. Additional studies are needed to further define the optimal use of LHRH agonists within various patient risk groups.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
P. Mongiat-Artus, P. Teillac,